FM HAS EXERCISED MODERATION IN ROLLBACK OF STIMULUS
FY'11 DIVESTMENT TARGET AT RS.40,000 CRORE
PLAN OUTLAY FOR ENERGY SECTOR IN FY'11 ESTIMATED AT RS.1.46 LAKH CRORE
FY'11 CUSTOMS REVENUES ESTIMATED AT RS.1.15 LK CRORE
TO SPEND RS.1.16 LK CRORE IN FY'11 ON SUBSIDIES
FY'11 CORPORATE TAX REVENUE ESTIMATED AT RS.3.01 LK CRORE
FY'11 INCOME TAX REVENUE ESTIMATED AT RS.1.21 LK CRORE
FY'11 EXCISE REVENUE ESTIMATED AT RS.1.32 LK CRORE
FY'11 PETROLEUM SUBSIDIES ESTIMATED AT RS.3100 CR
TO SPEND RS.49980 CR ON FERTILISER SUBSIDY IN FY'11
FY'11 DIVESTMENT TARGET AT RS.40,000 CRORE
FY'11 DIVESTMENT TARGET AT RS.40,000 CR
NET REVENUE GAIN FROM TAX PROPOSALS AT RS.20500 CRORE
NET GAIN FROM INDIRECT TAX PROPOSALS SEEN AT RS.46,500 CRORE
DIRECT TAX PROPOSALS TO RESULT IN REVENUE LOSS OF RS.26000 CRORE
NEWS AGENCIES TO BE EXEMPT FROM SERVICE TAX
TO BRING SEVERAL SERVICES WITHIN THE PURVIEW OF SERVICE TAX
JEWELLERY STOCKS RISE AS GOVT RAISES DUTY ON GOLD, SILVER IMPORTS
GOVT TO KEEP SERVICE TAX UNCHANGED AT 10%
CUSTOMS DUTY ON KEY INPUTS FOR MICROWAVES CUT TO 5% VS 10%
EXCISE ON LOCALLY REFINED GOLD AT RS.280/GM
BASIC CUSTOMS DUTY ON GOLD ORE REDUCED
CUSTOMS DUTY ON SILVER AT RS.1500/KG
TO RAISE DUTY ON GOLD IMPORTS TO RS.300/10 GRAMS
TO RAISE DUTY ON GOLD AND SILVER IMPORTS
4% EXCISE DUTY IMPOSED ON ELECTRIC CARS AND VEHICLES
CUSTOMS DUTY RATIONALISED ON MUSIC, GAMING AND SOFTWARE
UNIFORM, CONCESSIONAL 5% DUTY ON ALL MEDICAL APPLIANCES
COMPOSTABLE POLYMER IMPORTS EXEMPT FROM BASIC CUSTOMS DUTY
TO GRANT PROJECT IMPORT STATUS FOR MONORAILS
CONCESSIONAL 5% CUSTOMS DUTY ON SET UP OF SOLAR POWER UNIT
EXCISE DUTY ON CFL HALVED TO 4%
IMPOSED 4% EXCISE DUTY ON ELECTRIC CARS AND VEHICLES
TO WAIVE EXCISE DUTY ON PHOTOVOLTAIC AND SOLAR PANELS
PARTS OF WIND ENERGY ROTORS EXEMPTED FROM CENTRAL EXCISE DUTY
TO LEVY CLEAN ENERGY CESS OF RS.50/TONNE ON COAL
WIND ROTORS EXEMPTED FROM CENTRAL EXCISE DUTY
SVC TAX EXEMPTION ON TRANSPORTATION OF PULSES AND CEREALS BY ROAD
EXCISE ON LARGE CARS, SUV AND MUV RAISED TO 22%
ROLLBACK IN EXCISE DUTY TO 10% VS 8%
CONCESSIONAL CUSTOMS DUTY OF 5% ON AGRI MACHINES
SERVICE TAX EXEMPTED ON TRANSPORTATION BY ROAD
OPPOSITION MEMBERS WALK OUT FROM THE PARLIAMENT
5% SERVICE TAX EXEMPTION FOR COLD STORAGE UNITS
TO PARTIALLY ROLL BACK CENTRAL EXCISE DUTY ON PETROL PDTS TO 10%
EXCISE DUTY ON ALL CIGARS AND CIGARETTES TO GO UP
CENTRAL EXCISE DUTY ON PETROL AND DIESEL RAISED BY RS.1/LITRE
RAISED EXCISE DUTY ON ALL NON SMOKING TOBACCO
TO RESTORE 7.5% DUTY ON PETROL AND DIESEL
TO RESTORE 5% DUTY ON CRUDE PETROLEUM
CENTRAL EXCISE DUTY ON PETROL AND DIESEL RAISED TO RS.1/LITRE
GOVT ANNOUNCES PARTIAL ROLLBACK IN EXCISE DUTY
EXCISE ON LARGE CARS, SUV AND MUV RAISED TO 22%
ROLLBACK IN EXCISE DUTY TO 10% VS 8%
MAT TO BE RAISED TO 18% VS 15%
PRESUMPTIVE TAX LIMIT RAISED TO RS.60 LAKH
NO TAX ON INCOME UPTO RS.1.6 LAKH
INVESTMENT LINKED DEDUCTION BENEFIT FOR 2 STAR HOTELS
TO REDUCE CURRENT SURCHARGE ON COMPANIES TO 7.5% FROM 10%
WEIGHTED DEDUCTION ON R&D RAISED TO 200% VS 150%
TO REDUCE CURRENT SURCHARGE ON COMPANIES TO 7.5%
30% TAX SLAB ON INCOME OF RS.8 LAKH AND ABOVE
MAT TO BE RAISED TO 18% VS 15%
10% TAX SLAB ON INCOME BETWEEN RS.1.6 - RS.5 LAKH
TAX SLAB OF 20% FOR INCOME BETWEEN RS.5-8 LAKH
DEDUCTION OF RS.20K TOWARDS INVESTMENT IN INFRA BONDS
NO TAX ON INCOME UPTO RS.1.6 LAKH
10% TAX SLAB ON INCOME BETWEEN RS.1.6 - RS.5 LAKH
TO BROADEN CURRENT TAX SLABS
IT DEPT TO NOTIFY SARAL 2 FORM FOR INDIVIDUALS
BORROWING PLAN TO BE DECIDED IN CONSULTATION WITH RBI
GOVT TO BRING SUBSIDY RELATED LIABILITY INTO FISCAL ACCOUNTING
FY'11 NET MARKET BORROWING PEGGED AT RS.3.45 LAKH CRORE
FY'11 BUDGET DEFICIT SEEN AT 5.5% OF GDP: PRANAB MUKHERJEE
BUDGET DEFICIT IN FY'10 ESTIMATED AT 6.9% OF GDP
GOVT TO EXTEND CASH SUBSIDY AND NOT ISSUE OIL BONDS
FY'12 FISCAL DEFICIT SEEN AT 4.8%; FY'13 FISCAL DEFICIT TARGET AT 4.1%
FISCAL DEFICIT TARGET AT 5.5% FOR FY'11
EXPENDITURE (PLAN AND NON-PLANNED) FOR FY'11 AT RS.11.9 LKH CR
GROSS TAX RECEIPTS SEEN AT RS.7.46 LAKH CRORE IN FY'11
DEFENCE CAPEX RAISED TO RS.60,000 CRORE IN FY'11
ALLOCATION FOR DEFENSE RAISED TO RS.1.47 LAKH CRORE
ALLOCATION OF RS.1900 CRORE FOR UID PROJECT IN FY'11
UID AUTHORITY TO ROLL OUT 1ST SET OF ID CARDS BY END OF THIS YEAR
HOME LOANS UPTO RS.10 LAKH TO GET 1% INTEREST SUBVENTION UPTO MAR'11
UNORGANISED WORKERS INCLUDE WEAVERS, RICKSHAW PULLERS
GOVT TO SET UP SOCIAL SECURITY FUND FOR UNORGANISED WORKERS
SOCIAL SECURITY FUND TO HAVE A CORPUS OF OVER RS.1000 CRORE
GOVT TO SET UP SOCIAL SECURITY FUND FOR UNORGANISED WORKERS
HOME LOANS UPTO RS.20 LAKH TO GET 1% INTEREST SUBVENTION UPTO MAR'11
ALLOCATION FOR RAJIV AWAAS YOJANA RAISED TO RS.1270 CRORE IN FY'11
TO ALLOCATE RS.10000 CRORE FOR THE INDIRA AWAS YOJANA
ALLOCATION TO NREGA RAISED TO RS.41000 CR IN FY'11
TO ALLOCATE RS.48000 CRORE FOR BHARAT NIRMAN IN FY'11
TO INCREASE PLAN ALLOCATION FOR SCHOOL EDUCATION TO RS.31600 CRORE
SOCIAL SECTOR SPENDING IN FY'11 SEEN AT RS.1.38 LAKH CRORE
GOVT TO ROLLOUT GST AND DIRECT TAX CODE BY APRIL 1, 2011
TO PROVIDE RS.1.73 LAKH CRORE (46% OF PLAN ALLOCATION) FOR INFRA
TO EXTEND INTEREST SUBVENTION FOR HOUSING LOANS UPTO RS. 20 LAKH
GOVT TO ROLLOUT GST AND DIRECT TAX CODE BY APRIL 1, 2011
HAVE PROVIDED RS.1200 CR ASSISTANCE FOR DROUGHT IN BUNDELKHAND
TO ALLOCATE RS.48000 CRORE FOR BHARAT NIRMAN IN FY'11
SOCIAL SECTOR SPENDING IN FY'11 SEEN AT RS.1.38 LAKH CRORE
ALLOCATION TO NREGA RAISED TO RS.41000 CR IN FY'11
GOVT TO PROVIDE RS.66100 CRORE FOR RURAL DEVELOPMENT IN FY'11
TO ALLOCATE RS.22300 CRORE TO HEALTH MINISTRY IN FY'11
TO INCREASE PLAN ALLOCATION FOR SCHOOL EDUCATION TO RS.31600 CRORE
SOCIAL SECTOR SPENDING IN FY'11 SEEN AT RS.1.38 LAKH CRORE
25% OF PLAN ALLOCATION TO BE GIVEN FOR DEVELOPMENT OF RURAL INFRA
GOVT READY WITH THE DRAFT FOOD SECURITY BILL
TO PROVIDE 1 TIME GRANT TO TAMIL NADU GOVT FOR TIRUPUR EXPORTS
TO ESTABLISH NATIONAL CLEAN ENERGY FUND FOR INNOVATIVE PROJECTS
PLAN OUTLAY FOR RENEWABLE ENERGY RAISED TO RS.1000 CR VS RS.600 CR
COAL REGULATORY AUTHORITY TO CREATE LEVEL PLAYING FIELD IN COAL SECTOR
IIFCL DISBURSEMENTS AT RS.9000 CRORE BY MARCH 2010
IIFCL DISBURSEMENTS SEEN AT RS.20000 CRORE BY MARCH 2011
TO INTRODUCE COMPETITIVE BIDDING FOR COAL BLOCKS FOR CAPTIVE MINING
ALLOCATION TO POWER SECTOR AT RS.5130 CRORE IN FY'11
IIFCL TO DOUBLE REFINANCING TO BANKS FOR INFRA SECTOR IN FY'11
IIFCL DISBURSEMENTS SEEN AT RS.20000 CRORE BY MARCH 2011
ALLOCATION TO ROAD INFRA RAISED TO RS.19894 CRORE
IIFCL DISBURSEMENTS AT RS.9000 CRORE BY MARCH 2010
ALLOCATION TO ROAD INFRA RAISED TO RS. 19894 CRORE
TO PROVIDE RS.1.73 LAKH CRORE (46% OF PLAN ALLOCATION) FOR INFRA
CROP LOAN INTEREST SUBVENTION FOR TIMELY REPAYMENT RAISED TO 2%
FARM LOAN REPAYMENT PERIOD EXTENDED TO JUNE 30, 2010
EFFECTIVE INTEREST RATE FOR TIMELY PAYMENT NOW AT 5% FOR FARMERS
PERIOD OF REPAYMENT TO BE EXTENDED TO JUNE 30, 2010 FOR AGRI LOAN WAIVER
PERIOD OF REPAYMENT TO BE EXTENDED TO JUNE 30, 2010 FOR AGRI WAIVER
FARM CREDIT TARGET RAISED TO RS.3.75 LAKH CRORE FOR FY'11
GOVT TO GIVE RS.300 CRORE FOR RASHTRIYA KRISHI VIKAS YOJANA
GOVT TO TAKE A FIRM VIEW ON OPENING UP RETAIL TRADE
GOVT TO GIVE RS.200 CRORE TO LAUNCH CLIMATE RESILIENT AGRI INITIATIVES
FOUR PRONGED STRATEGY TO ENSURE GROWTH IN FARM SECTOR
TO PROVIDE RS.400 CRORE TO BOOST FARM OUTPUT IN EASTERN INDIA
ADDITIONAL SUM OF RS.16500 CRORE FOR FY'11 FOR BANK RECAPITALISATION
GOVT TO EXTEND INT SUBVENTION OF 2% ON PRE AND POST SHIPMENT CREDIT
GOVT TO PROVIDE FURTHER CAPITAL TO STRENGTHEN RURAL BANKS
ADDITIONAL SUM OF RS.16500 CRORE FOR FY'11 FOR BANK RECAPITALISATION
GOVT TO ROLLOUT GST AND DIRECT TAX CODE BY APRIL 1, 2011
ADDITIONAL SUM OF RS.16500 CRORE FOR FY'11 FOR BANK RECAPITALISTION
RBI CONSIDERING ADDITION BANKING LICENSES TO PRIVATE PLAYERS
COUNCIL FOR MACRO SUPERVISION OF LARGE CONGLOMERATES AND ECONOMY
GOVT TO CONSOLIDATE FDI GUIDELINES INTO A SINGLE DOCUMENT
GOVT INTENDS TO MAKE FDI MORE USER FRIENDLY
OWNERSHIP AND CONTROL BEING RECOGNISED A CENTRAL TO FDI POLICY
APRIL-DEC FDI INFLOWS AT $20.9 BILLION
FDI FLOWS DURING FY'10 HAVE BEEN STEADY
OIL MIN TO TAKE DECISION ON KIRIT PARIKH REPORT IN DUE COURSE
NUTRIENT BASED FERTILISER PRICES FOR FY'11 TO BE AROUND CURRENT MRP
DIVESTMENT PROCEEDS BUDGETED HIGHER IN FY'11 VS FY'10
NMDC, SVJN STAKE SALE TO FETCH RS.25000 CRORE IN FY'10
NEED TO REVIEW THE STIMULUS AND MOVE TOWARDS FISCAL CONSOLIDATION
GOVT TO ROLLOUT GST AND DIRECT TAX CODE BY APRIL 1, 2011
DIRECT TAX CODE LIKELY TO BE IN PLACE FROM APRIL 2011
Source: www.bseindia.com
Friday, February 26, 2010
Intraday Trading Calls for 26th February
Indian Stock Market may open flat to positive and remains highly volatile for the day today. As there is union budget today.
Today's Intraday Stock Tips / Trading Calls (Keep strict Stop Loss for Each Trade):
SCRIP NAME | TRIGGER | PRICE | TARGET 1 | TARGET 2 |
IDFC | Buy Above | 153.00 | 157.20 | 161.00 |
Sell Below | 151.35 | 148.45 | 145.00 | |
APTECH LTD. | Buy Above | 165.05 | 170.55 | 176.00 |
Sell Below | 162.15 | 158.10 | 154.00 | |
CEAT LTD. | Buy Above | 134.70 | 138.65 | 142.00 |
Sell Below | 132.55 | 129.20 | 126.00 | |
ATLANTA | Buy Above | 180.00 | 186.55 | 192.00 |
Sell Below | 177.05 | 172.40 | 168.00 | |
GODREJ INDUSTRIES | Buy Above | 153.10 | 158.70 | 164.00 |
Sell Below | 150.00 | 147.10 | 143.00 | |
ASHOK LEYLAND | Buy Above | 47.20 | 48.75 | 52.00 |
Sell Below | 46.05 | 44.50 | 43.00 | |
ESCORTS LTD. | Buy Above | 128.20 | 132.60 | 137.00 |
Sell Below | 126.40 | 123.15 | 120.00 |
GOOD LUCK
Saturday, February 20, 2010
Stock Idea: JB Chemicals & Pharma
JB Chemicals & Pharma. Ltd— BUY—66—INR
Sector — Pharmaceuticals
Regd.Off.— Neelam Centre, Hind Cycle Road, Worli, Mumbai - 400030
Listed — NSE, BSE.
Company overview—
J. B. Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing, professionally managed, global pharmaceutical companies manufacturing a wide range of innovative specialty medicines for domestic and international markets. A flagship company of the Unique Group, it is also known as "Unique". J. B. Chemicals & Pharmaceuticals Ltd. known to many, as Unique Pharmaceutical Laboratories is one of India’s leading global pharmaceutical companies. The company manufactures and markets a wide range of pharmaceutical formulations, herbal remedies, bulk drugs, intermediates and radio-diagnostics. J B Chemical & Pharmaceuticals Ltd. is a customer driven, financially sound company, consistently enhancing value for its shareholders by rewarding them with healthy dividends year after year. It has a large global presence with operations in over 50 countries across the globe. Over 50% of the Company’s revenue comes from exports to USA, Europe, Latin America, Africa, and South East Asia. To further enhance its strength in foreign markets, company has also entered into joint venture and strategic tie-ups with key partners in USA etc.
Products & Services—
Its product portfolio consists of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs). Some of the products within these categories enjoy leadership positions in the Indian and foreign markets. Company is strategically focused on R&D and totally committed to respond promptly to market needs by developing quality products at affordable prices for the masses. With a strong base of 11 state-of-the-art manufacturing units (including 3 US FDA approved Tablet & API plants) and two DSTC approved R&D centers, the company has entered a dynamic phase of expansion into newer and faster growing therapeutic segments such as anti-diabetics, CNS and Respiratory. It manufactures basic chemicals, petrochemicals, pharmaceuticals, photographic chemicals and agro-based products. Its product portfolio includes metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine). It has a fully automated 100 per cent EOU lozenges plant of capacity 400 million units par annum at Daman, manufacturing hard catidies.
J. B. Chemical & Pharmaceuticals Ltd.'s top four brands are Doktor Mom, Metrogyl, Rantac, Nicardia, OF. API products are not offered in countries where valid patents exist. However, final responsibility with respect to third party's patent rights in a specific country lies exclusively with the user." In formulations company manufactures ANTHELMINTICS, ANTI DIARRHOEAL, ANTIBIOTICS & CHEMOTHERAPEUTIC AGENTS, ANTIDIABETIC, ANTIHISTAMINE SYSTEMIC, CARDIOVASCULAR/CARDIC CARE, G.I/PROKINETIC, G.I/ANTIULCERANT, NASAL DECONGESTANTS, NEURO / PSYCHIATRY, NSAID's/ANTIRHEUMATIC, NUTRITIONAL & TONICS, RADIODIAGNOSTICS, SEX STIMULANTS, UROLOGY, COUGH & COLD, TROPICAL PREPRATIONS, TROPICAL ANTIBACTERIAL/ANTISEPTIC, DENTAL PREPARATIONS, MULTIVITAMINS & REJUVENTORS, SEX STIMULANTS, HERBAL PREPARATIONS.
Research & Developments—
R&D is the lifeblood of J. B. Chemicals & Pharmaceuticals Ltd. Company’s scientists has discovered 20 New Molecules in NSAID therapeutic segments. Two state-of-the-art R&D laboratories at Mumbai & Ankleshwar match superior standards. Its current and future R&D activities focus on development of Generic Products for Regulated Markets.
Recent News—
Company has received US food and drug administration (USFDA) approval to the abbreviated new drug application (ANDA) for Cetirizine 5 mg. and 10 mg. tablets. These formulations have been found to be bioequivalent to the innovator McNeil Consumer Healthcare’s product "Zyrtech". Cetirizine tablets are now sold over the counter (OTC) in USA. It has sales of about USD 1.4 billion in USA prior to it became OTC product. Company would manufacture these formulations at its state of the art manufacturing facility at Panoli (Gujrat), which has already been classified as acceptable and GMP compliant by USFDA. Company is in the process of negations with its marketing partners in USA for the launch of these products in USA. The approval has potential to further strengthen the company’s Rest of the World (RoW) business that has shown good growth in the last several years.
Valuation—
At current market price, stock is trading at 5.6 P/E multiple of its FY2011 estimated earnings. We recommend investors to Buy "JB chemicals and Pharmaceuticals ltd." for medium to long-term investment horizon.
Sector — Pharmaceuticals
Regd.Off.— Neelam Centre, Hind Cycle Road, Worli, Mumbai - 400030
Listed — NSE, BSE.
Company overview—
J. B. Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing, professionally managed, global pharmaceutical companies manufacturing a wide range of innovative specialty medicines for domestic and international markets. A flagship company of the Unique Group, it is also known as "Unique". J. B. Chemicals & Pharmaceuticals Ltd. known to many, as Unique Pharmaceutical Laboratories is one of India’s leading global pharmaceutical companies. The company manufactures and markets a wide range of pharmaceutical formulations, herbal remedies, bulk drugs, intermediates and radio-diagnostics. J B Chemical & Pharmaceuticals Ltd. is a customer driven, financially sound company, consistently enhancing value for its shareholders by rewarding them with healthy dividends year after year. It has a large global presence with operations in over 50 countries across the globe. Over 50% of the Company’s revenue comes from exports to USA, Europe, Latin America, Africa, and South East Asia. To further enhance its strength in foreign markets, company has also entered into joint venture and strategic tie-ups with key partners in USA etc.
Products & Services—
Its product portfolio consists of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs). Some of the products within these categories enjoy leadership positions in the Indian and foreign markets. Company is strategically focused on R&D and totally committed to respond promptly to market needs by developing quality products at affordable prices for the masses. With a strong base of 11 state-of-the-art manufacturing units (including 3 US FDA approved Tablet & API plants) and two DSTC approved R&D centers, the company has entered a dynamic phase of expansion into newer and faster growing therapeutic segments such as anti-diabetics, CNS and Respiratory. It manufactures basic chemicals, petrochemicals, pharmaceuticals, photographic chemicals and agro-based products. Its product portfolio includes metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine). It has a fully automated 100 per cent EOU lozenges plant of capacity 400 million units par annum at Daman, manufacturing hard catidies.
J. B. Chemical & Pharmaceuticals Ltd.'s top four brands are Doktor Mom, Metrogyl, Rantac, Nicardia, OF. API products are not offered in countries where valid patents exist. However, final responsibility with respect to third party's patent rights in a specific country lies exclusively with the user." In formulations company manufactures ANTHELMINTICS, ANTI DIARRHOEAL, ANTIBIOTICS & CHEMOTHERAPEUTIC AGENTS, ANTIDIABETIC, ANTIHISTAMINE SYSTEMIC, CARDIOVASCULAR/CARDIC CARE, G.I/PROKINETIC, G.I/ANTIULCERANT, NASAL DECONGESTANTS, NEURO / PSYCHIATRY, NSAID's/ANTIRHEUMATIC, NUTRITIONAL & TONICS, RADIODIAGNOSTICS, SEX STIMULANTS, UROLOGY, COUGH & COLD, TROPICAL PREPRATIONS, TROPICAL ANTIBACTERIAL/ANTISEPTIC, DENTAL PREPARATIONS, MULTIVITAMINS & REJUVENTORS, SEX STIMULANTS, HERBAL PREPARATIONS.
Research & Developments—
R&D is the lifeblood of J. B. Chemicals & Pharmaceuticals Ltd. Company’s scientists has discovered 20 New Molecules in NSAID therapeutic segments. Two state-of-the-art R&D laboratories at Mumbai & Ankleshwar match superior standards. Its current and future R&D activities focus on development of Generic Products for Regulated Markets.
Recent News—
Company has received US food and drug administration (USFDA) approval to the abbreviated new drug application (ANDA) for Cetirizine 5 mg. and 10 mg. tablets. These formulations have been found to be bioequivalent to the innovator McNeil Consumer Healthcare’s product "Zyrtech". Cetirizine tablets are now sold over the counter (OTC) in USA. It has sales of about USD 1.4 billion in USA prior to it became OTC product. Company would manufacture these formulations at its state of the art manufacturing facility at Panoli (Gujrat), which has already been classified as acceptable and GMP compliant by USFDA. Company is in the process of negations with its marketing partners in USA for the launch of these products in USA. The approval has potential to further strengthen the company’s Rest of the World (RoW) business that has shown good growth in the last several years.
Valuation—
At current market price, stock is trading at 5.6 P/E multiple of its FY2011 estimated earnings. We recommend investors to Buy "JB chemicals and Pharmaceuticals ltd." for medium to long-term investment horizon.
Source: Internet (Valuenotes by Abhishek Jain)
Thursday, February 18, 2010
Intraday Trading Calls for 18th February
Indian Stock Market may open flat to positive and remains flat with high volatility for the day today. A good positive closing expected.
Today's Intraday Stock Tips / Trading Calls (Keep strict Stop Loss for Each Trade):
SCRIP NAME | TRIGGER | PRICE | TARGET 1 | TARGET 2 |
SASKEN COMM. | Buy Above | 180.55 | 186.35 | 192.00 |
Sell Below | 178.05 | 173.20 | 168.00 | |
APTECH LTD. | Buy Above | 173.20 | 178.55 | 184.00 |
Sell Below | 171.15 | 167.35 | 162.00 | |
IDFC | Buy Above | 150.00 | 154.75 | 158.00 |
Sell Below | 148.55 | 144.20 | 140.00 | |
ATLANTA | Buy Above | 190.70 | 196.25 | 202.00 |
Sell Below | 188.05 | 183.10 | 178.00 | |
GODREJ INDUSTRIES | Buy Above | 161.20 | 165.70 | 170.00 |
Sell Below | 159.30 | 155.60 | 151.00 | |
PRISM CEMENT | Buy Above | 52.00 | 54.15 | 56.00 |
Sell Below | 51.05 | 49.55 | 48.00 | |
WALCHAND NAGAR IND | Buy Above | 250.00 | 258.65 | 268.00 |
Sell Below | 244.55 | 237.15 | 230.00 |
GOOD LUCK
Stock Idea: KEC International Ltd.
This RPG group company, a global leader in the project management business has posted a good set of results for the third quarter ended 31st Dec 2009.
The company’s net sales were at Rs. 937.66, up 8% on a QoQ and 6% on a YoY. PBT was up at Rs.63.61 crore, up 15% on a QoQ and 66% on a YoY. Net profit QoQ grew 15% and 68% on a YoY at Rs.41.99 crore. Growth in topline was lackluster as most of the orders came in only during the end and hence did not have enough time to be executed and get reflected in the numbers.
The company’s order book is at an all time high at Rs. 6051 crore as on date, of which Rs.1800 crore came in during Q3. Of this 53% comes from the South Asia market and the balance 47% from the International market. Most of these are to be executed in FY10.
Raw material costs have started rising and we can see some this getting reflected in Q3 itself. It rose sequentially from Rs.430.97 crore to Rs.479.94 crore. And given the rate of inflation, this cost component is only expected to rise further.
For 9MFY10, net sales was at Rs.2192.25 crore and net profit was at Rs.116.57 crore. As against this, for 12MFY09, the net sales was at Rs.3427.67 crore and net profit was at Rs.116.29 crore. So the company’s net profit will surely surpass that of FY09 and that makes it a safe bet.
The company’s net sales were at Rs. 937.66, up 8% on a QoQ and 6% on a YoY. PBT was up at Rs.63.61 crore, up 15% on a QoQ and 66% on a YoY. Net profit QoQ grew 15% and 68% on a YoY at Rs.41.99 crore. Growth in topline was lackluster as most of the orders came in only during the end and hence did not have enough time to be executed and get reflected in the numbers.
The company’s order book is at an all time high at Rs. 6051 crore as on date, of which Rs.1800 crore came in during Q3. Of this 53% comes from the South Asia market and the balance 47% from the International market. Most of these are to be executed in FY10.
Raw material costs have started rising and we can see some this getting reflected in Q3 itself. It rose sequentially from Rs.430.97 crore to Rs.479.94 crore. And given the rate of inflation, this cost component is only expected to rise further.
For 9MFY10, net sales was at Rs.2192.25 crore and net profit was at Rs.116.57 crore. As against this, for 12MFY09, the net sales was at Rs.3427.67 crore and net profit was at Rs.116.29 crore. So the company’s net profit will surely surpass that of FY09 and that makes it a safe bet.
Source: Internet (premiuminvestments.in by S P Tulsian)
Stock Idea: Indian Bank
Indian Bank posted, for the third quarter ended 31st Dec 2009, a YoY 11.44% rise in total income at rs.2308.29 crore. Net Interest Income improved by 21.31% to Rs.872.97 crore. Operating profit was up 19.35% at Rs.690.67 crore. Net Profit was at Rs. 441.38, up 25.86%. What really helped the bottomline was cost control of deposits. It also focused more on the quality of credit and concentrated more on sectors like sugar, power, pharma, cement, steel of different sectors. The company remains conservative in the retail sector but prefers to lend towards education and gold, where the bank says recovery is around 96%.
NIM was at 3.82% compared to 3.91% in Q3FY09. Its Capital Adequacy as per Basel I norms improved to 13.15% against 12.68 % as in Q3FY09. And as per Basel II norms, it improved to 13.75% v/s 13.09% YoY.
Gross NPAs declined to 0.89% (Rs.514.27 crore) as on 31.12.2009, from 0.92% (Rs.462.46 crore) as on 31.12.2008 and Net NPAs was maintained at 0.16%. During the nine months, total NPA recovery was Rs.471.07 crore.
Total Business of the Bank measured in terms of total deposits and gross advances increased to Rs.1,42,200 crore, up from Rs.1,20,120 crore recording a growth of Rs.22,080 crore (18.38%). Total Deposits rose by 21.64% (Rs.15,072 crore) to Rs.84,732 crore from Rs.69,660 crore. Gross Advances increased by 13.89% (Rs.7008 crore) to Rs.57,468 crore from Rs.50,460 crore.
Total number of branches in India as at 31/12/09 stood at 1702 branches. It opened 60 new branches till Q3FY10 and by Q4, hopes to open 40 more.
Indian Bank for 9Mfy10 had a total revenue of Rs.6713.05 crore and net profit of Rs.1145.03 crore. For FY09, total revenue was at Rs.6830.33 crore and net profit was at Rs.1245.32 crore. Clearly the bank will end FY10 on a much higher note, net profit is expected to be around Rs.1450 crore.
NIM was at 3.82% compared to 3.91% in Q3FY09. Its Capital Adequacy as per Basel I norms improved to 13.15% against 12.68 % as in Q3FY09. And as per Basel II norms, it improved to 13.75% v/s 13.09% YoY.
Gross NPAs declined to 0.89% (Rs.514.27 crore) as on 31.12.2009, from 0.92% (Rs.462.46 crore) as on 31.12.2008 and Net NPAs was maintained at 0.16%. During the nine months, total NPA recovery was Rs.471.07 crore.
Total Business of the Bank measured in terms of total deposits and gross advances increased to Rs.1,42,200 crore, up from Rs.1,20,120 crore recording a growth of Rs.22,080 crore (18.38%). Total Deposits rose by 21.64% (Rs.15,072 crore) to Rs.84,732 crore from Rs.69,660 crore. Gross Advances increased by 13.89% (Rs.7008 crore) to Rs.57,468 crore from Rs.50,460 crore.
Total number of branches in India as at 31/12/09 stood at 1702 branches. It opened 60 new branches till Q3FY10 and by Q4, hopes to open 40 more.
Indian Bank for 9Mfy10 had a total revenue of Rs.6713.05 crore and net profit of Rs.1145.03 crore. For FY09, total revenue was at Rs.6830.33 crore and net profit was at Rs.1245.32 crore. Clearly the bank will end FY10 on a much higher note, net profit is expected to be around Rs.1450 crore.
Source: Internet (premiuminvestments.in by S P Tulsian)
Stock Idea: Ashok Leyland
Despite the impending fear of an interest rate hike and expectation of an excise duty hike in the Budget, Ashok Leyland has been moving strong on the bourses. If 2009 was a year dominated by the passenger cars sales surge, looks like 2010 would be year when we will see the commercial vehicle segments showing robust growth.
India’s second- biggest truck maker reported an over times YoY rise in truck sales in January 10’ at 7,871 units from 2,444 units a year earlier. And the god news is that it has reduced the number of vehicles in stock by 1,200 in January and this cut in inventory will continue into March too. As per the new plans, the company aims to hold no more than three weeks of stocks.
Its third quarter ended 31st Dec 2009 was its best for the entire fiscal. If it had begun Q1FY10 on a very somber note, the indications are that it will end the year on a high note. In Q3, sales and net profit have almost doubled from that we saw in Q1. There has been a significant improvement in the profit margins too. OPM for Q3 was at 11.41%, up from 10.82% sequentially and from 7.86% in Q1. NPM has also risen, from a meager 0.85% in Q1 and 5.62% in Q2 to 5.76% in Q3. Apart from the surge in sales, what has also helped is the consistent reduction in operating costs. Its interest costs, which were a matter great concern earlier are now significantly low.
For 9MFY10, the company’s net sales stood at Rs.4305.66 crore v/s Rs.5981.07 crore for 12MFY09. Net profit was at Rs.201.01 crore v/s Rs.190 crore. There is no doubt that the company would end FY10 on a very high note. But at the same time also keep in mind impact of the base effect, which will automatically make FY10 look extremely good.
Higher steel and tyre costs might prompt the company to hike its prices, which when compared with Tata Motors, is already on the higher side. It is expected to end FY10, with a NPM, which would be over 10%. The outlook looks bright but it has to watch out for increasing competition from M&M and MAN.
Source: Internet (premiuminvestments.in by S P Tulsian)
India’s second- biggest truck maker reported an over times YoY rise in truck sales in January 10’ at 7,871 units from 2,444 units a year earlier. And the god news is that it has reduced the number of vehicles in stock by 1,200 in January and this cut in inventory will continue into March too. As per the new plans, the company aims to hold no more than three weeks of stocks.
Its third quarter ended 31st Dec 2009 was its best for the entire fiscal. If it had begun Q1FY10 on a very somber note, the indications are that it will end the year on a high note. In Q3, sales and net profit have almost doubled from that we saw in Q1. There has been a significant improvement in the profit margins too. OPM for Q3 was at 11.41%, up from 10.82% sequentially and from 7.86% in Q1. NPM has also risen, from a meager 0.85% in Q1 and 5.62% in Q2 to 5.76% in Q3. Apart from the surge in sales, what has also helped is the consistent reduction in operating costs. Its interest costs, which were a matter great concern earlier are now significantly low.
For 9MFY10, the company’s net sales stood at Rs.4305.66 crore v/s Rs.5981.07 crore for 12MFY09. Net profit was at Rs.201.01 crore v/s Rs.190 crore. There is no doubt that the company would end FY10 on a very high note. But at the same time also keep in mind impact of the base effect, which will automatically make FY10 look extremely good.
Higher steel and tyre costs might prompt the company to hike its prices, which when compared with Tata Motors, is already on the higher side. It is expected to end FY10, with a NPM, which would be over 10%. The outlook looks bright but it has to watch out for increasing competition from M&M and MAN.
Source: Internet (premiuminvestments.in by S P Tulsian)
Wednesday, February 17, 2010
Intraday Trading Calls for 17th February
Indian Stock Market may open positive and remains positive with high volatility for the day today. A good positive closing expected.
Today's Intraday Stock Tips / Trading Calls (Keep strict Stop Loss for Each Trade):
SCRIP NAME | TRIGGER | PRICE | TARGET 1 | TARGET 2 |
SASKEN COMM. | Buy Above | 178.65 | 184.55 | 190.00 |
Sell Below | 176.45 | 172.10 | 168.00 | |
GODREJ INDUSTRIES | Buy Above | 148.75 | 154.35 | 160.00 |
Sell Below | 147.35 | 144.20 | 140.00 | |
IDFC | Buy Above | 149.20 | 153.40 | 158.00 |
Sell Below | 147.40 | 143.15 | 140.00 | |
ATLANTA | Buy Above | 192.60 | 199.25 | 205.00 |
Sell Below | 190.00 | 185.10 | 180.00 | |
VIDEOCON INDUSTRIES | Buy Above | 220.10 | 228.05 | 235.00 |
Sell Below | 216.35 | 210.25 | 205.00 | |
SELAN EXPLO | Buy Above | 430.10 | 440.35 | 450.00 |
Sell Below | 422.35 | 415.05 | 405.00 | |
ONMOBILE | Buy Above | 370.25 | 378.90 | 390.00 |
Sell Below | 364.50 | 357.15 | 348.00 |
Short To Medium Term Delivery Buy: Natco Pharma (524816) CMP Rs. 127/- Target Rs. 155 - 170/-.
GOOD LUCK
Tuesday, February 16, 2010
Intraday Trading Calls for 16th February
Indian Stock Market may open positive and remains positive with high volatility for the day today. A good positive closing expected.
Today's Intraday Stock Tips / Trading Calls (Keep strict Stop Loss for Each Trade):
SCRIP NAME | TRIGGER | PRICE | TARGET 1 | TARGET 2 |
SASKEN COMM. | Buy Above | 178.65 | 184.55 | 190.00 |
Sell Below | 176.45 | 172.10 | 168.00 | |
MBL INFRA | Buy Above | 212.75 | 218.25 | 224.00 |
Sell Below | 209.35 | 203.70 | 198.00 | |
IDFC | Buy Above | 148.25 | 152.30 | 156.00 |
Sell Below | 146.70 | 143.15 | 140.00 | |
ATLANTA | Buy Above | 190.60 | 196.75 | 204.00 |
Sell Below | 187.45 | 182.55 | 178.00 | |
JYOTI STRUCTURE | Buy Above | 172.10 | 177.45 | 182.00 |
Sell Below | 169.35 | 165.25 | 160.00 | |
JAI HIND PROJECTS | Buy Above | 175.10 | 180.60 | 186.00 |
Sell Below | 172.40 | 168.10 | 163.00 | |
APTECH | Buy Above | 171.55 | 178.40 | 184.00 |
Sell Below | 169.05 | 164.15 | 160.00 |
GOOD LUCK
Stock Idea : Hexaware Technologies Ltd
Stocks idea : Hexaware Technologies Ltd— BUY—75—INR
Sector — Software
Regd.Off.— 152, M.B.Park, Sector-3, Mahape, Navi Mumbai - 400710
Listed — NSE, BSE.
Company overview—
Hexaware is a global provider of IT and Process outsourcing services incorporated in the year 1990. It specializes in Enterprise solutions, Application Management, EAI, e-Commerce, and Embedded Systems. Hexaware has experience in managing large IT applications in real time as well as high value services around packaged enterprise applications such as SAP and PeopleSoft. Hexaware is organized along three main client-facing groups. These are: Global Competency Group, Service Delivery and Sales Geographies. It offers software services for the banking, finance, insurance, healthcare, transportation and hospitality industries. Company has offices in India in the cities of Chennai, Mumbai, Delhi and Pune. Hexaware’s global operations are located in North America, Europe and Asia Pacific. It also has a regional office in Princeton, New Jersey.
Products & Services—
Company provides its services to Banking & financial services, insurance, Transportation & Hospitality, Healthcare sector basically. Company provides services into architecture consulting, development, maintenance, re-engineering, integration, e-business services, SAP services, Oracle services, peoplesoft services, CRM, business intelligence, HR BPO services, HR IT services, HR consulting services, Design and support services etc. Hexaware is a global provider of IT and Process outsourcing services. It focuses exclusively on maximizing client returns from outsourcing and off shoring. Company have extensive experience in managing large IT applications in real time as well as in providing high value services around packaged enterprise applications such as SAP and PeopleSoft. Its experience in the business process-outsourcing arena fully complements and strengthens its service spectrum and allows it to operate as an enterprise class solution delivery company. Its solutions aim to provide high value by optimizing cost of ownership of technology investments for customers. Hexaware has a client base comprising several Global 1000 organizations. Its commitment is to provide solutions that translate into tangible business outcomes for customers. Its”partner-in-business” approach generates high business value for customers and rich dividends to Hexaware in the form of a continual stream of repeat business. Hexaware’s domain capability expertise and reduced learning curves enables significant compression in time-to-value deliverables. Company applies a robust Key Account Management process to find more ways to delight key customers and grow market share to further strengthens its customer-centricphilosophy.
Company's onsite / offshore delivery model provides significant cost savings. Its development centers are assessed at SEI CMMI-Level 5, and are also ISO 9001:2000 and TickIT certified. These help it to continually provide high value, high quality deliverables to its clients. Valuation—
Sector — Software
Regd.Off.— 152, M.B.Park, Sector-3, Mahape, Navi Mumbai - 400710
Listed — NSE, BSE.
Company overview—
Hexaware is a global provider of IT and Process outsourcing services incorporated in the year 1990. It specializes in Enterprise solutions, Application Management, EAI, e-Commerce, and Embedded Systems. Hexaware has experience in managing large IT applications in real time as well as high value services around packaged enterprise applications such as SAP and PeopleSoft. Hexaware is organized along three main client-facing groups. These are: Global Competency Group, Service Delivery and Sales Geographies. It offers software services for the banking, finance, insurance, healthcare, transportation and hospitality industries. Company has offices in India in the cities of Chennai, Mumbai, Delhi and Pune. Hexaware’s global operations are located in North America, Europe and Asia Pacific. It also has a regional office in Princeton, New Jersey.
Products & Services—
Company provides its services to Banking & financial services, insurance, Transportation & Hospitality, Healthcare sector basically. Company provides services into architecture consulting, development, maintenance, re-engineering, integration, e-business services, SAP services, Oracle services, peoplesoft services, CRM, business intelligence, HR BPO services, HR IT services, HR consulting services, Design and support services etc. Hexaware is a global provider of IT and Process outsourcing services. It focuses exclusively on maximizing client returns from outsourcing and off shoring. Company have extensive experience in managing large IT applications in real time as well as in providing high value services around packaged enterprise applications such as SAP and PeopleSoft. Its experience in the business process-outsourcing arena fully complements and strengthens its service spectrum and allows it to operate as an enterprise class solution delivery company. Its solutions aim to provide high value by optimizing cost of ownership of technology investments for customers. Hexaware has a client base comprising several Global 1000 organizations. Its commitment is to provide solutions that translate into tangible business outcomes for customers. Its”partner-in-business” approach generates high business value for customers and rich dividends to Hexaware in the form of a continual stream of repeat business. Hexaware’s domain capability expertise and reduced learning curves enables significant compression in time-to-value deliverables. Company applies a robust Key Account Management process to find more ways to delight key customers and grow market share to further strengthens its customer-centricphilosophy.
Company's onsite / offshore delivery model provides significant cost savings. Its development centers are assessed at SEI CMMI-Level 5, and are also ISO 9001:2000 and TickIT certified. These help it to continually provide high value, high quality deliverables to its clients. Valuation—
Company is open to inorganic expansion and would consider any good buy in the remote infrastructure management and BPO spaces. With USD 79.5 million cash in hand, funding will not pose a problem and that the company is interested in companies in North America and Western Europe. At current market price, stock is trading at attractive valuation of 7.14 P/E multiple of its FY2011 estimated EPS. We recommend investors to buy “Hexaware Technologies Limited” with medium to long-term investment horizon.
Source: Internet (Valuenotes by Abhishek Jain)
Monday, February 15, 2010
Intraday Trading Calls for 15th February
Indian Stock Market may open positive and remains positive with high volatility for the day today. A good positive closing expected.
Today's Intraday Stock Tips / Trading Calls (Keep strict Stop Loss for Each Trade):
SCRIP NAME | TRIGGER | PRICE | TARGET 1 | TARGET 2 |
SASKEN COMM. | Buy Above | 179.60 | 184.55 | 190.00 |
Sell Below | 177.25 | 172.70 | 168.00 | |
IDBI | Buy Above | 118.00 | 121.65 | 125.00 |
Sell Below | 116.50 | 113.60 | 110.00 | |
IDFC | Buy Above | 145.70 | 150.20 | 155.00 |
Sell Below | 144.05 | 141.15 | 138.00 | |
ATLANTA | Buy Above | 185.65 | 191.25 | 198.00 |
Sell Below | 183.05 | 178.70 | 174.00 | |
WALCHAND NAGAR IND. | Buy Above | 248.25 | 255.25 | 262.00 |
Sell Below | 245.00 | 240.35 | 235.00 | |
JAI HIND PROJECTS | Buy Above | 168.75 | 175.20 | 182.00 |
Sell Below | 165.40 | 161.35 | 156.00 | |
APTECH LTD. | Buy Above | 170.00 | 176.10 | 182.00 |
Sell Below | 167.35 | 163.15 | 158.00 |
GOOD LUCK
Subscribe to:
Posts (Atom)